Precigen, Inc. (PGEN)
7.135
+0.12
(+1.78%)
USD |
NASDAQ |
Sep 03, 16:00
7.135
0.00 (0.00%)
After-Hours: 20:00
Precigen Research and Development Expense (TTM) : 31.01M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.01M |
| March 31, 2026 | 35.22M |
| December 31, 2025 | 40.06M |
| September 30, 2025 | 44.83M |
| June 30, 2025 | 43.82M |
| March 31, 2025 | 47.14M |
| December 31, 2024 | 51.23M |
| September 30, 2024 | 52.78M |
| June 30, 2024 | 53.31M |
| March 31, 2024 | 50.70M |
| December 31, 2023 | 48.61M |
| September 30, 2023 | 46.41M |
| June 30, 2023 | 47.45M |
| March 31, 2023 | 47.53M |
| December 31, 2022 | 47.17M |
| September 30, 2022 | 48.56M |
| June 30, 2022 | 48.37M |
| March 31, 2022 | 49.60M |
| December 31, 2021 | 48.32M |
| September 30, 2021 | 32.53M |
| June 30, 2021 | 30.27M |
| March 31, 2021 | 26.56M |
| December 31, 2020 | 27.36M |
| September 30, 2020 | 16.80M |
| June 30, 2020 | 32.29M |
| Date | Value |
|---|---|
| March 31, 2020 | 51.06M |
| December 31, 2019 | 66.67M |
| September 30, 2019 | 354.07M |
| June 30, 2019 | 364.59M |
| March 31, 2019 | 378.40M |
| December 31, 2018 | 388.73M |
| September 30, 2018 | 154.04M |
| June 30, 2018 | 154.33M |
| March 31, 2018 | 146.29M |
| December 31, 2017 | 143.21M |
| September 30, 2017 | 133.68M |
| June 30, 2017 | 126.25M |
| March 31, 2017 | 120.61M |
| December 31, 2016 | 112.29M |
| September 30, 2016 | 109.46M |
| June 30, 2016 | 102.03M |
| March 31, 2016 | 94.03M |
| December 31, 2015 | 147.48M |
| September 30, 2015 | 135.38M |
| June 30, 2015 | 125.54M |
| March 31, 2015 | 117.67M |
| December 31, 2014 | 48.65M |
| September 30, 2014 | 45.10M |
| June 30, 2014 | 42.35M |
| March 31, 2014 | 41.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Geron Corp. | 73.89M |
| Neurocrine Biosciences, Inc. | 1.131B |
| Elicio Therapeutics, Inc. | 23.51M |
| Agenus, Inc. | 57.69M |
| Amgen, Inc. | 7.638B |